Valuation: Aclaris Therapeutics, Inc.

Market Cap 743M 645M 599M 553M 1.04B 70.93B 1.06B 7.1B 2.78B 35.23B 2.79B 2.73B 118B P/E 2026 *
-8.2x
P/E 2027 * -6.68x
Enterprise Value 607M 528M 490M 452M 851M 57.99B 867M 5.8B 2.27B 28.8B 2.28B 2.23B 96.85B EV / Sales 2026 *
106x
EV / Sales 2027 * 115x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
1 day-2.82%
1 week+0.19%
Current month-0.95%
1 month-1.87%
3 months+18.82%
6 months+45.15%
Current year+74.09%
1 week 5.01
Extreme 5.01
5.62
1 month 5.01
Extreme 5.01
5.88
Current year 2.49
Extreme 2.49
5.88
1 year 1.5
Extreme 1.5
5.88
3 years 0.59
Extreme 0.5902
10.15
5 years 0.59
Extreme 0.5902
19.97
10 years 0.59
Extreme 0.5902
33.25
Manager TitleAgeSince
Chief Executive Officer 56 2024-01-16
President 67 2024-11-17
Director of Finance/CFO 39 2022-12-31
Director TitleAgeSince
Chairman 56 2022-12-31
Director/Board Member 50 2014-08-31
Director/Board Member 59 2016-08-31
Date Insider Type Main position Quantity % Market Cap.
3/1/26 Fiscal year

Chief Financial Officer

5,427 0.0050%
2/3/26 Fiscal year

Executive/Senior Manager

47,687 0.0440%
2/3/26 Fiscal year

Chief Financial Officer

50,499 0.0466%
Change 5-day change 1-year change 3-year change Capi.($)
-2.82%+0.19%+242.48%-46.91% 743M
-0.81%-0.33%+27.15%+81.12% 55.23B
-0.83%-7.83%+24.73%+62.23% 53.75B
-0.78%+3.41%-14.07%-15.15% 23.48B
-3.68%-5.87%-6.19%+355.59% 22B
+2.49%-0.92%+20.31%-12.15% 19.78B
-0.09%-1.70%+28.45%-33.75% 17.44B
+0.58%-5.88%+16.30%+540.37% 14.66B
-3.10%-1.10%+51.19%+177.83% 14.07B
-5.09%-10.87%+153.11%+272.20% 13.02B
Average -1.40%-2.28%+54.35%+138.14% 23.42B
Weighted average by Cap. -1.02%-0.47%+27.30%+121.26%

Financials

2026 *2027 *
Net sales 5.71M 4.96M 4.61M 4.25M 8M 545M 8.15M 54.55M 21.36M 271M 21.45M 20.98M 911M 5.36M 4.65M 4.32M 3.99M 7.51M 512M 7.64M 51.17M 20.03M 254M 20.12M 19.68M 854M
Net income -84.78M -73.64M -68.39M -63.07M -119M -8.09B -121M -810M -317M -4.02B -318M -311M -13.52B -103M -89.04M -82.69M -76.26M -144M -9.79B -146M -979M -383M -4.86B -385M -377M -16.35B
Net Debt -136M -118M -109M -101M -190M -12.95B -193M -1.29B -507M -6.43B -509M -498M -21.62B -125M -108M -101M -92.91M -175M -11.92B -178M -1.19B -467M -5.92B -469M -459M -19.92B
Logo Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
71
Date Price Change Volume
26-07-31 US$5.240 -1.50% 197,786
26-07-30 US$5.320 +3.91% 1,905,224
26-07-29 US$5.120 -3.94% 1,177,994
26-07-28 US$5.330 -0.74% 1,552,980
26-07-27 US$5.370 +2.68% 4,860,252
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.320USD
Average target price
10.00USD
Spread / Average Target
+87.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACRS Stock